title: A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
abstract: BACKGROUND
  Although etanercept is used as a continuous therapy for moderate to severe plaque psoriasis, intermittent use may be necessary in some instances.
  
  
  OBJECTIVE
  In this randomized, open-label study, we evaluated the effectiveness and safety of continuous versus interrupted etanercept therapy.
  
  
  METHODS
  All patients received uninterrupted etanercept 50 mg twice weekly during the first 12 weeks, followed by either continuous (n = 1272) or interrupted (n = 1274) etanercept 50 mg once weekly in the next 12 weeks. The primary effectiveness end point was the proportion of responders (those who achieved a Physician's Global Assessment [PGA] score <or=2 and improvement from baseline) at week 24. Secondary end points included the PGA "clear/almost clear" status, the PGA Scalp Psoriasis score, and the Dermatology Life Quality Index. A modified intent-to-treat analysis was performed.
  
  
  RESULTS
  At week 12, comparable high proportions of responders were reported in the continuous (71.3%) and interrupted (72.0%) arms. However, the proportion of responders at week 24 was greater in the continuous group than in the interrupted group (71.0% vs 59.5%; P < .0001). Similar results were observed in secondary end points. The mean number of etanercept doses (1 dose = 50 mg) received by patients in the continuous group was 33.4, compared with 28.0 in the interrupted group. Etanercept was well tolerated in both treatment arms.
  
  
  CONCLUSIONS
  We examined one round of discontinuation and re-treatment; interrupted therapy provided less total medication to responding patients.
  
  
  CONCLUSIONS
  Continuous and interrupted etanercept therapy was effective and generally well tolerated in patients with psoriasis, with greater improvements observed in the continuous arm at week 24. Most patients regained their response after reinitiation of etanercept.
authors.affiliation: Arlington Center for Dermatology, TX 76011, USA. acdermatology@yahoo.com
authors.forename: Angela
authors.initials: A
authors.lastname: Moore
authors.forename: Kenneth B
authors.initials: KB
authors.lastname: Gordon
authors.forename: Sewon
authors.initials: S
authors.lastname: Kang
authors.forename: Alice
authors.initials: A
authors.lastname: Gottlieb
authors.forename: Bruce
authors.initials: B
authors.lastname: Freundlich
authors.forename: H Amy
authors.initials: HA
authors.lastname: Xia
authors.forename: Seth R
authors.initials: SR
authors.lastname: Stevens
mesh_terms: D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000175:diagnosis* / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept